How Can Institutional Review Boards Best Interpret Preclinical
Data?
article has not abstract
Vyšlo v časopise:
How Can Institutional Review Boards Best Interpret Preclinical
Data?. PLoS Med 8(3): e32767. doi:10.1371/journal.pmed.1001011
Kategorie:
Perspective
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1001011
Souhrn
article has not abstract
Zdroje
1. KimmelmanJLondonAJ
2011
Predicting harms and benefits in translational trials: Ethics,
evidence, and uncertainty.
PLoS Med
8
3
e1001011
doi:10.1371/journal.pmed.1001011
2. SuntharalingamGPerryMRWardSCastello-CortesA
Brett Sj
2006
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal
antibody TGN1412.
N Engl J Med
355
1018
1028
3. FlemingN
2008
Study claims to solve drug trial mystery.
The Telegraph (London)
Available: http://www.telegraph.co.uk/news/uknews/1540591/Study-claims-to-solve-drug-trial-mystery.html.
Accessed 31 January 2011.
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2011 Číslo 3
- Jak rozpoznat pacienty s familiární hypercholesterolémií ve své praxi
- Myasthenia gravis: kombinace chirurgie a farmakoterapie jako nejefektivnější modalita?
- Statinová intolerance
- DESATORO PRE PRAX: Aktuálne odporúčanie ESPEN pre nutričný manažment u pacientov s COVID-19
- Mutace v genu PCSK9 zodpovědné za rozvoj familiární hypercholesterolémie
Najčítanejšie v tomto čísle
- The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices
- How Can Institutional Review Boards Best Interpret Preclinical Data?
- HIV-1 Drug Resistance Emergence among Breastfeeding Infants Born to HIV-Infected Mothers during a Single-Arm Trial of Triple-Antiretroviral Prophylaxis for Prevention of Mother-To-Child Transmission: A Secondary Analysis
- Predicting Harms and Benefits in Translational Trials: Ethics, Evidence, and Uncertainty